Advaxis, Inc. (ADXS)
Advaxis, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Advaxis, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. Advaxis, Inc. was incorporated in 2017 and is headquartered in Rehovot, Israel.
$852.67K
Mr. Kenneth Berlin
35.00
Princeton, NEW JERSEY
Jul 28, 2005
0.00
$-7.99
0.20
0.30
-369,784.62%
-0.00
0.00
-0.00
65.59
0.30
-289.96%
962.69%
Similar stocks (2)
Aeterna Zentaris Inc.
AEZS
Guardion Health Sciences, Inc.
GHSI
Similar stocks (2)
Aeterna Zentaris Inc.
AEZS
Guardion Health Sciences, Inc.
GHSI